Mission Statement

AureoGen’s mission is to develop a novel genetic-engineering technology that will propel the company into a leading position in the discovery and production of cyclic peptide-based drugs

About Us

AureoGen Biosciences was incorporated on August 12, 2003. AureoGen’s primary focus is the development of novel, genetic engineering technologies for the discovery and production of cyclic peptide-based drugs. Until recently, any structural modifications required for conversion of a native cyclic peptide molecule into a functional drug had to be introduced by complicated and expensive synthetic chemistry. This hampered the development of promising drug candidates, as well as prevented optimization (such as reduction of side effects) of many existing drugs. AureoGen is developing a novel technology that allows efficient, cost-effective modification, optimization and production of cyclic peptide base drugs. Recent advances in the understanding of the biology and genetics of cyclic peptide producing organisms have produced tools and knowledge which allow many types of modifications (to cyclic peptides) to be introduced by altering the sequence of the genes encoding the cyclic peptide generating non-ribosomal peptide synthase (NRPS) complexes, in the producer organisms. Engineering of these genes allows for the design of organisms capable of producing cyclic peptides with the properties required for a finished drug molecule, or a molecule requiring only minor chemical modifications. Utilizing this knowledge, AureoGen is developing a set of (genetic) tools that will greatly reduce the production cost of cyclic peptide-based drug molecules requiring structural modifications. AureoGen’s technology also allows for efficient and cost-effective in-depth exploration of the pharmacological properties of virtually any cyclic peptide, as well as simple and economical generation of entirely novel cyclic peptides.